The ABC's of Carcinoid and Neuroendocrine Tumors

Three of the world’s leading carcinoid and NET cancer specialists – Dr. Richard R.P. Warner, Dr. Edward M. Wolin, and Dr. Eugene A. Woltering  – talk about the advice they offer their patients, the advances they have seen during their careers, and what they anticipate will be available for NET patients in the future. (Click on the words YouTube in the bottom right of the video to see it in a larger size).

The Latest News

NET Cancer Blogger and Advocate Finalist in WEGO Health Activist Awards

Ronny Allan, @NETCancerBlog, is a finalist in two of the 2016 WEGO Health Activist Awards categories — Best in Show Blog and Best in Show Community.  The winner of those awards will be announced on Tuesday, December 6 at 6 pm, Eastern Standard Time.  Good luck, Ronny!  Read more

Call for Nominations: 7th Annual Warner Advocacy Award

Novartis Oncology and The NET Alliance have announced that nominations are open for the 7th Annual Warner Advocacy Award. This annual award was established by Novartis in 2009 in honor of Monica Warner, who passed away in August 2009, to recognize the patient, supporter, or caregiver who most embodies the passion, dedication, leadership, and spirit with which Monica assisted those affected by neuroendocrine tumors. Monica was an everyday NET hero who inspired the community through her passionate involvement. Nominations are now being accepted and all submissions are due by midnight, EST, on Tuesday, November 29. Read more

Join Our #14DaysOfGratitude

Check out our video Fighting NET Cancer with Grace & Gratitude and tell us about your appreciation for the things that matter most to you in the 14 days between NET Cancer Day and Thanksgiving.  Tell us about your friends, family, support group members, vacations, life milestones, hobbies that you love, etc.  You can post on CCF’s Facebook page, on Twitter at @CarcinoidNETs, or on our blog post in the Comments section. Please use the hashtag #14DaysOfGratitude. Thanks for your support!

Project Zebra Report: Real-World Insights from the Carcinoid and NET Patient Community

In honor of Worldwide NET Cancer Awareness Day, we are pleased to release the first ever Project Zebra Report: Real-World Insights from the Carcinoid and Neuroendocrine Tumor Patient Community, a collaboration between our partner Self Care Catalysts and the Carcinoid Cancer Foundation. Read more

Reaching Those Who Are Still Undiagnosed

To combat statistics showing that it often takes 5 to 7 years for patients to receive the correct diagnosis of a neuroendocrine tumor (NET), the Carcinoid Cancer Foundation has partnered with Advanced Accelerator Applications to create an infographic listing common symptoms and misdiagnoses.  Please share this broadly in hopes of helping others get the proper diagnosis more quickly. Download the infographic here.

Carcinoid/Neuroendocrine Specialist Announces Retirement from Medical Practice

Dr. Richard R.P. Warner, Director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai Hospital, has announced that he is retiring from his medical practice at Mount Sinai, as of November 1, 2016. Read more

Stanford Health Care in California Launches Neuroendocrine Tumor Multidisciplinary Program

A new multidisciplinary Neuroendocrine Cancer center at Stanford Health Care in California has been established to improve the standard of care for NET patients and to advance the study of these rare diseases. Pamela Kunz, MD, is the Medical Director of the NET program. Read more

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

Breaking news on June 1, 2016 from the U.S. Food and Drug Administration! The FDA has approved NETSPOT, “the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.”   Read more from the FDA and Read more from Advanced Acclerator Applications

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected by early 2017.  Additionally, an Expanded Access Program (EAP) in the United States for the investigational product, Lutathera, is expected to begin in about 2 months at 2-5 institutions. Read more